The pharmaceutical company Lexeo Therapeutics has announced positive updates from their phase I/II trial of the gene therapy LX2006 to treat cardiomyopathy in Friedreich’s ataxia (FA). Â
Interim data has shown sustained or deepening improvements in most participants across both cardiac and neurological measures of FA.
This includes clinically meaningful improvement in the modified Friedreich Ataxia Rating Scale (mFARS), showing a slowed disease progression and improved function.
Following this, Lexeo are in discussions with the FDA about an accelerated approval pathway for LX2006. They plan to start a registrational trial in the first half of 2026, and are currently exploring UK sites.
Read Lexeo’s letter to the community here.
Read more about the trial here.
